Photoacoustic Chemical Imaging of Tumor Microenvironment pH for Prediction of Chemotherapeutic Efficacy in Breast Cancer
Source abstract
Abstract
An acidic microenvironment is a hallmark of solid tumors, which occurs due to cancer cells' preferential utilization of aerobic glycolysis. Both in vitro and in vivo studies provide evidence that clinicians can exploit this acidity by selecting drugs whose efficacy is particularly affected by the tumor microenvironment (TME). However, noninvasive measurement of tumor pH remains challenging. Photoacoustic chemical imaging enhanced by pH-sensitive nanoparticles as contrast agents is a promising technique to address this need. This imaging technique was employed to quantitatively monitor the TME pH in mice bearing patient-derived xenografts undergoing simultaneous alkalization treatment and chemotherapy. Compared to controls, in alkalinized tumors, paclitaxel chemotherapy significantly reduced tumor size, increased tumor necrosis, and reduced cancer cell proliferation as validated by histopathology and immunohistochemistry. Thus, photoacoustic chemical imaging of TME pH may provide significant predictive value and represents a promising noninvasive, reliable technology for realizing personalized cancer chemotherapy.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Photoacoustic and Ultrasonic Imaging · Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biomedical Engineering
University of Michigan
Department of Pathology
University of Michigan Medical School
Rogel Cancer Center
Funding
Rogel Cancer Center, University of Michigan · National Institutes of Health · Prostate Cancer Foundation
References (62)
Show source-provided references
1. 10.1098/rstb.2013.009910.1098/rstb.2013.0099 ↗
2. 10.3390/cancers1209248410.3390/cancers12092484 ↗
3. 10.1007/s10555-018-09778-x10.1007/s10555-018-09778-x ↗
4. 10.1042/BST2016009410.1042/BST20160094 ↗
5. 10.1158/2326-6066.CIR-18-033710.1158/2326-6066.CIR-18-0337 ↗
6. 10.1038/onc.2015.47710.1038/onc.2015.477 ↗
7. 10.1038/nrc171310.1038/nrc1713 ↗
8. 10.1016/j.biopen.2016.01.00110.1016/j.biopen.2016.01.001 ↗
9. 10.1016/j.neo.2019.03.00410.1016/j.neo.2019.03.004 ↗
10. 10.1158/0008-5472.CAN-12-279610.1158/0008-5472.CAN-12-2796 ↗
11. 10.3390/cancers1504132010.3390/cancers15041320 ↗
12. 10.1021/mp200292c10.1021/mp200292c ↗
13. 10.1016/S0006-2952(03)00467-210.1016/S0006-2952(03)00467-2 ↗
14. 10.1016/S0006-2952(03)00468-410.1016/S0006-2952(03)00468-4 ↗
15. 10.1080/15384101.2021.194910610.1080/15384101.2021.1949106 ↗
16. 10.1016/S0022-5347(17)37290-710.1016/S0022-5347(17)37290-7 ↗
17. 10.1016/j.canlet.2010.05.01010.1016/j.canlet.2010.05.010 ↗
18. 10.1159/00035391510.1159/000353915 ↗
19. 10.3390/cancers904003610.3390/cancers9040036 ↗
20. 10.1158/0008-5472.CAN-06-098310.1158/0008-5472.CAN-06-0983 ↗
21. 10.1007/s11307-010-0457-z10.1007/s11307-010-0457-z ↗
22. 10.1039/C5NR06162H10.1039/C5NR06162H ↗
23. 10.1177/153473542092257910.1177/1534735420922579 ↗
24. 10.7554/eLife.1569110.7554/eLife.15691 ↗
25. 10.1021/acsami.3c0973310.1021/acsami.3c09733 ↗
26. 10.1021/acsami.2c1049310.1021/acsami.2c10493 ↗
27. 10.1016/j.jconrel.2019.01.00410.1016/j.jconrel.2019.01.004 ↗
28. 10.1007/s10555-019-09782-910.1007/s10555-019-09782-9 ↗
29. 10.3389/fonc.2022.100358810.3389/fonc.2022.1003588 ↗
30. 10.1158/0008-5472.CAN-07-557510.1158/0008-5472.CAN-07-5575 ↗
31. 10.1021/acs.analchem.8b0479710.1021/acs.analchem.8b04797 ↗
32. 10.1038/s41467-017-00598-110.1038/s41467-017-00598-1 ↗
33. 10.1021/acs.analchem.0c0480410.1021/acs.analchem.0c04804 ↗
34. 10.1002/adma.20150319410.1002/adma.201503194 ↗
35. 10.1016/j.jpap.2024.10024110.1016/j.jpap.2024.100241 ↗
36. 10.1021/acsnano.2c0950210.1021/acsnano.2c09502 ↗
37. 10.3390/bios1310092310.3390/bios13100923 ↗
38. 10.1364/BOE.39337010.1364/BOE.393370 ↗
39. 10.1038/nrclinonc.2012.6110.1038/nrclinonc.2012.61 ↗
40. Swamy M. K. · 2022 · 287
41. 10.3390/ijms23191193710.3390/ijms231911937 ↗
42. 10.18632/oncotarget.1777510.18632/oncotarget.17775 ↗
43. 10.1259/bjro.2023001910.1259/bjro.20230019 ↗
44. 10.1016/j.bspc.2020.10196710.1016/j.bspc.2020.101967 ↗
45. 10.1007/s10334-014-0433-810.1007/s10334-014-0433-8 ↗
46. 10.1007/s11307-016-1029-710.1007/s11307-016-1029-7 ↗
47. 10.1002/nbm.490610.1002/nbm.4906 ↗
48. 10.1038/sj.bjc.669045510.1038/sj.bjc.6690455 ↗
49. 10.1248/bpb.b21-0007610.1248/bpb.b21-00076 ↗
50. 10.21873/anticanres.1402010.21873/anticanres.14020 ↗
51. 10.1038/bjc.1997.20110.1038/bjc.1997.201 ↗
52. 10.1016/j.bbadis.2020.16601110.1016/j.bbadis.2020.166011 ↗
53. 10.1016/B978-0-323-90951-8.00007-210.1016/B978-0-323-90951-8.00007-2 ↗
54. 10.1073/pnas.77.3.156110.1073/pnas.77.3.1561 ↗
55. 10.1016/S0021-9258(19)57363-X10.1016/S0021-9258(19)57363-X ↗
56. 10.3389/fimmu.2024.130258710.3389/fimmu.2024.1302587 ↗
57. 10.1016/j.bcp.2024.11617810.1016/j.bcp.2024.116178 ↗
58. 10.3390/cancers1522549310.3390/cancers15225493 ↗
59. 10.3390/pharmaceutics1302024210.3390/pharmaceutics13020242 ↗
60. Gerweck L. E. · Cancer Res. · 1996 · 56 · 1194
61. 10.1016/S0165-2478(02)00031-710.1016/S0165-2478(02)00031-7 ↗
62. 10.3389/fonc.2022.98171810.3389/fonc.2022.981718 ↗